Disease Overview
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| SALVIANOLIC ACID B | ? unclear | Mechanistic | DGIdb | |
| CANDOXATRIL | ? unclear | Mechanistic | DGIdb | |
| CILAZAPRIL | ↓ inhibits | Mechanistic | DGIdb | |
| TP0556351 | ↓ inhibits | Mechanistic | DGIdb | |
| PRAVASTATIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| SILDENAFIL | ? unclear | Mechanistic | DGIdb | |
| GEMFIBROZIL | ? unclear | Mechanistic | DGIdb | |
| RESCINNAMINE | ? unclear | Mechanistic | DGIdb | |
| SPIRAPRIL | ? unclear | Mechanistic | DGIdb | |
| INDOMETHACIN | ? unclear | Mechanistic | DGIdb | |
| HYDROCHLOROTHIAZIDE | ? unclear | Mechanistic | DGIdb | |
| ARGIPRESSIN | ? unclear | Mechanistic | DGIdb | |
| METOPROLOL | ? unclear | Mechanistic | DGIdb | |
| DELAPRIL | ↓ inhibits | Mechanistic | DGIdb | |
| ACETYLCHOLINE | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC GLUCOCORTICOID | ? unclear | Mechanistic | DGIdb | |
| IMIDAPRIL | ↓ inhibits | Mechanistic | DGIdb | |
| MALATHION | ↓ inhibits | Mechanistic | DGIdb | |
| MOEXIPRIL | ? unclear | Mechanistic | 56.0 nM (IC50) | DGIdb |
| VORINOSTAT | ? unclear | Mechanistic | DGIdb | |
| ILEPATRIL | ↓ inhibits | Mechanistic | DGIdb | |
| RXP470.1 | ↓ inhibits | Mechanistic | DGIdb | |
| CGS-27023A | ? unclear | Mechanistic | DGIdb | |
| NITROPRUSSIDE | ? unclear | Mechanistic | DGIdb | |
| ENALAPRILAT ANHYDROUS | ↓ inhibits | Mechanistic | 1.2 nM (IC50) | DGIdb |
| TORSEMIDE | ? unclear | Mechanistic | DGIdb | |
| ATORVASTATIN CALCIUM TRIHYDRATE | ? unclear | Mechanistic | DGIdb | |
| FOSINOPRIL | ? unclear | Mechanistic | DGIdb | |
| FUROSEMIDE | ? unclear | Mechanistic | DGIdb | |
| TEMOCAPRIL HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| BENAZEPRIL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CARBARIL | ↓ inhibits | Mechanistic | DGIdb | |
| BUPROPION HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| QUINAPRIL | ? unclear | Mechanistic | 8.3 nM (IC50) | DGIdb |
| COMPOUND 1 [PMID: 24900526] | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 20 [PMID: 22153340] | ↓ inhibits | Mechanistic | DGIdb | |
| BUMETANIDE | ? unclear | Mechanistic | DGIdb | |
| GALLOPAMIL | ? unclear | Mechanistic | DGIdb | |
| FLUOXETINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| AZD6605 | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 229 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ANTIVIRAL AGENT | ? unclear | Mechanistic | DGIdb | |
| IBALIZUMAB | ? unclear | Mechanistic | DGIdb | |
| CLENOLIXIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| HERBIMYCIN | ? unclear | Mechanistic | DGIdb | |
| ZANOLIMUMAB | ? unclear | Mechanistic | DGIdb | |
| CEDELIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| VRC-01LS | ~ modulates | Mechanistic | DGIdb | |
| TREGALIZUMAB | ↑ activates | Mechanistic | DGIdb | |
| PRILIXIMAB | ~ modulates | Mechanistic | DGIdb | |
| TRX1 | ? unclear | Mechanistic | DGIdb | |
| ANTISENSE OLIGONUCLEOTIDES | ? unclear | Mechanistic | DGIdb | |
| TRX-1 | ↓ inhibits | Mechanistic | DGIdb | |
| ANTI-THYMOCYTE GLOBULIN | ? unclear | Mechanistic | DGIdb | |
| SEMZUVOLIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| KELIXIMAB | ~ modulates | Mechanistic | DGIdb | |
| ISOCOMPLESTATIN | ↓ inhibits | Mechanistic | 130.0 nM (IC50) | ChEMBL |
| CHLOROPEPTIN | ↓ inhibits | Mechanistic | 130.0 nM (IC50) | ChEMBL |
| CHEMBL3143464 | ↓ inhibits | Mechanistic | 130.0 nM (IC50) | ChEMBL |
| CHEMBL3138360 | ↑ activates | Mechanistic | 73000.0 nM (EC50) | ChEMBL |
| CHEMBL3138345 | ↑ activates | Mechanistic | 22000.0 nM (EC50) | ChEMBL |
| CHEMBL3138187 | ↑ activates | Mechanistic | 4000.0 nM (EC50) | ChEMBL |
| CHEMBL3138374 | ↑ activates | Mechanistic | 69600.0 nM (EC50) | ChEMBL |
| CHEMBL3138095 | ↑ activates | Mechanistic | 19900.0 nM (EC50) | ChEMBL |
| CHEMBL3138378 | ↑ activates | Mechanistic | 70400.0 nM (EC50) | ChEMBL |
| CHEMBL3138119 | ↑ activates | Mechanistic | 83800.0 nM (EC50) | ChEMBL |
| CHEMBL231224 | ↓ inhibits | Mechanistic | 80000.0 nM (Kd) | ChEMBL |
| CHEMBL267655 | ↓ inhibits | Mechanistic | 62000.0 nM (Kd) | ChEMBL |
| CHEMBL388209 | ↓ inhibits | Mechanistic | 20000.0 nM (Kd) | ChEMBL |
| CHEMBL230799 | ↓ inhibits | Mechanistic | 13000.0 nM (Kd) | ChEMBL |
| CHEMBL267658 | ↓ inhibits | Mechanistic | 26000.0 nM (Kd) | ChEMBL |
| CHEMBL388208 | ↓ inhibits | Mechanistic | 26000.0 nM (Kd) | ChEMBL |
| CHEMBL267657 | ↓ inhibits | Mechanistic | 16000.0 nM (Kd) | ChEMBL |
| CHEMBL230798 | ↓ inhibits | Mechanistic | 6000.0 nM (Kd) | ChEMBL |
| CHEMBL388207 | ↓ inhibits | Mechanistic | 27000.0 nM (Kd) | ChEMBL |
| CHEMBL230796 | ↓ inhibits | Mechanistic | 35000.0 nM (Kd) | ChEMBL |
| CHEMBL1852155 | ↓ inhibits | Mechanistic | 210.0 nM (IC50) | ChEMBL |
| CYCLOTRIAZADISULFONAMIDE HYDROCHLORIDE | ↓ inhibits | Mechanistic | 330.0 nM (IC50) | ChEMBL |
| CHEMBL4783030 | ↓ inhibits | Mechanistic | 2810.0 nM (IC50) | ChEMBL |
| CHEMBL4755141 | ↓ inhibits | Mechanistic | 860.0 nM (IC50) | ChEMBL |
| CHEMBL4783761 | ↓ inhibits | Mechanistic | 950.0 nM (IC50) | ChEMBL |
Showing top 40 of 52 agents ranked by evidence tier.
CYP27B1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| TENOFOVIR DISOPROXIL FUMARATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL2036072 | ? unclear | Mechanistic | DGIdb | |
| GAMMA-INTERFERON | ? unclear | Mechanistic | DGIdb | |
| DEFERASIROX | ? unclear | Mechanistic | DGIdb | |
| RIFAMPIN | ? unclear | Mechanistic | DGIdb | |
| TRICHOSTATIN A | ? unclear | Mechanistic | DGIdb | |
| DECITABINE | ? unclear | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2A | ? unclear | Mechanistic | DGIdb | |
| SOY PROTEIN ISOLATE | ? unclear | Mechanistic | DGIdb | |
| CTA091 | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL389014 | ↓ inhibits | Mechanistic | 554.0 nM (IC50) | ChEMBL |
| CHEMBL253613 | ↓ inhibits | Mechanistic | 616.0 nM (IC50) | ChEMBL |
| CHEMBL255088 | ↓ inhibits | Mechanistic | 554.0 nM (IC50) | ChEMBL |
| CHEMBL1170908 | ↓ inhibits | Mechanistic | 616.1 nM (IC50) | ChEMBL |
| CHEMBL4099180 | ↓ inhibits | Mechanistic | 60.2 nM (IC50) | ChEMBL |
| CHEMBL4081152 | ↓ inhibits | Mechanistic | 95.2 nM (IC50) | ChEMBL |
| CHEMBL4104395 | ↓ inhibits | Mechanistic | 570.0 nM (IC50) | ChEMBL |
| CHEMBL4074768 | ↓ inhibits | Mechanistic | 410.0 nM (IC50) | ChEMBL |
| KETOCONAZOLE | ↓ inhibits | Mechanistic | 340.0 nM (IC50) | ChEMBL |
IFNG
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| GANCICLOVIR | ? unclear | Mechanistic | DGIdb | |
| EMAPALUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PEFLOXACIN | ? unclear | Mechanistic | DGIdb | |
| TRETINOIN | ? unclear | Mechanistic | DGIdb | |
| AMITRIPTYLINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| MELPHALAN | ? unclear | Mechanistic | DGIdb | |
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| EDRECOLOMAB | ? unclear | Mechanistic | DGIdb | |
| METHYLPREDNISOLONE | ? unclear | Mechanistic | DGIdb | |
| DOXIFLURIDINE | ? unclear | Mechanistic | DGIdb | |
| CYCLOPHOSPHAMIDE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| URSODIOL | ? unclear | Mechanistic | DGIdb | |
| PREDNISONE | ? unclear | Mechanistic | DGIdb | |
| BLEOMYCIN | ? unclear | Mechanistic | DGIdb | |
| AMIKACIN | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC GLUCOCORTICOID | ? unclear | Mechanistic | DGIdb | |
| FONTOLIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| AMG-811 | ↓ inhibits | Mechanistic | DGIdb | |
| THEOPHYLLINE | ? unclear | Mechanistic | DGIdb | |
| PENICILLIN G POTASSIUM | ? unclear | Mechanistic | DGIdb | |
| TRASTUZUMAB | ? unclear | Mechanistic | DGIdb | |
| FUMARIC ACID | ? unclear | Mechanistic | DGIdb | |
| SURAMIN | ? unclear | Mechanistic | DGIdb | |
| IBUPROFEN, SODIUM SALT | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC MELATONIN | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC AUTOLOGOUS LYMPHOCYTES | ? unclear | Mechanistic | DGIdb | |
| THROMBIN ALFA | ? unclear | Mechanistic | DGIdb | |
| INTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT INTERLEUKIN-1-BETA | ? unclear | Mechanistic | DGIdb | |
| CHEMBL3288259 | ↓ inhibits | Mechanistic | 10000.0 nM (Kd) | ChEMBL |
| CHEMBL3288260 | ↓ inhibits | Mechanistic | 7000.0 nM (Kd) | ChEMBL |
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| NERELIMOMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CROMOLYN SODIUM | ? unclear | Mechanistic | DGIdb | |
| PLACULUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| METHYLENE BLUE | ? unclear | Mechanistic | DGIdb | |
| ALTEPLASE | ? unclear | Mechanistic | DGIdb | |
| CARBOPLATIN | ? unclear | Mechanistic | DGIdb | |
| GENTAMICIN | ? unclear | Mechanistic | DGIdb | |
| GOLIMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| BUPIVACAINE | ? unclear | Mechanistic | DGIdb | |
| PENTOXIFYLLINE | ? unclear | Mechanistic | 85000.0 nM (IC50) | DGIdb |
| BENZO[E]PYRENE | ? unclear | Mechanistic | DGIdb | |
| THALIDOMIDE | ? unclear | Mechanistic | DGIdb | |
| PYRAZINAMIDE | ? unclear | Mechanistic | DGIdb | |
| GLIMEPIRIDE | ? unclear | Mechanistic | DGIdb | |
| OMEPRAZOLE | ? unclear | Mechanistic | DGIdb | |
| LENERCEPT | ↓ inhibits | Mechanistic | DGIdb | |
| ADALIMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PRAZOSIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| REMTOLUMAB | ? unclear | Mechanistic | DGIdb | |
| MIDOSTAURIN | ? unclear | Mechanistic | DGIdb | |
| LENABASUM | ? unclear | Mechanistic | DGIdb | |
| MAGNESIUM SULFATE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| PICIBANIL | ? unclear | Mechanistic | DGIdb | |
| FLUOCINOLONE ACETONIDE | ? unclear | Mechanistic | DGIdb | |
| MILTEFOSINE | ? unclear | Mechanistic | DGIdb | |
| HOMIDIUM BROMIDE | ? unclear | Mechanistic | DGIdb | |
| OZORALIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PEGSUNERCEPT | ↓ inhibits | Mechanistic | DGIdb | |
| CERTOLIZUMAB PEGOL | ↓ inhibits | Mechanistic | DGIdb | |
| THERAPEUTIC HORMONE | ? unclear | Mechanistic | DGIdb | |
| NAFAMOSTAT | ? unclear | Mechanistic | DGIdb | |
| FOLIC ACID | ? unclear | Mechanistic | DGIdb | |
| ABBV-257 | ? unclear | Mechanistic | DGIdb | |
| RISPERIDONE | ? unclear | Mechanistic | DGIdb | |
| COVA322 | ? unclear | Mechanistic | DGIdb | |
| HYDROXYCHLOROQUINE | ? unclear | Mechanistic | DGIdb | |
| CERTOLIZUMAB | ? unclear | Mechanistic | DGIdb | |
| AN0128 | ? unclear | Mechanistic | DGIdb | |
| 5,7-DIHYDROXY-4-METHYLCOUMARIN | ? unclear | Mechanistic | DGIdb | |
| SORAFENIB | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 277 agents ranked by evidence tier.
Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.
Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hypothesize that low do...
Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A Canadian physician survey found that most physicians do not investigate for CS as a possibility in these situations...
This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible fo...
We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of thes...
Inflammatory Cardiovascular Diseases and Autoimmune Rheumatic Diseases (ICARDs) encompass cardiovascular involvement in connective tissue diseases, vasculitis, and primary inflammatory cardiac processes affecting all layers of the heart. ICARDs are associated with increased cardiovascular morbidity ...
This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving sta...
Background: Uveitis is a serious eye disease that can cause vision loss. Treatment sometimes causes serious side effects or does not work. Researchers want to learn more about uveitis and why some people develop it. Objective: To learn clinical and genetic factors that may make people develop uve...
A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis
Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute cellular cardiac allograft rejection (ACR), cardiac sarcoidosis (CS) and th...
This study aims to characterize the epidemiology of interstitial lung diseases (ILD) associated to connective tissue disease (CTD) in Mexico, and to study its correlation with the different comorbidities and treatments used, as well as the possible impacts of these factors on the outcome of progress...
This randomized pilot clinical trial aims to examine whether sample collection with Franseen-type needles are effective for the diagnosis of sarcoidosis, as defined by improved sample quality for pathological diagnosis compared to the conventional Menghini-type needle.
This is safety study. Subjects will be undergoing the surgical procedure of nerve biopsy. After routine surgery without grafting, patients develop swelling, redness, tenderness and dysesthesia at the biopsy site. In order to determine whether grafting is safe compared to not repairing the nerve, it ...
Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous. Diagnosis and screening of blood-relatives is very difficult as the disease pro...
In severe refractory sarcoidosis not responding to conventional immunosuppressive treatment, the third-line tumor necrosis factor (TNF)-alpha inhibitor infliximab is an alternative. Treatment duration is not known, although it has been suggested that relapse rates after withdrawal could be high. We ...
This research study is testing whether Mindfulness-Based Stress Reduction (MBSR) can help reduce fatigue in people with sarcoidosis. The study will also look at whether MBSR can improve symptoms of anxiety and depression. Participants will be placed into one of two groups: * One group will take pa...
Searched directly from “Sarcoidosis” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 5-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."